Endo introduces bladder cancer treatment
CHADDS FORD, Pa. Drug maker Endo Pharmaceuticals announced the introduction of a drug that it says fills an unmet need as a treatment for bladder cancer.
Endo has introduced Valstar (valrubicin), which is used to treat Bacille Calmette-Guerin-refractory carcinoma in situ, an aggressive form of the cancer. The drug is designed for patients who have exhausted all other treatments.
“Patients with recurrent carcinoma in situ bladdor tumors who fail additional therapy have been significantly underserved due to the lack of available approved treatment alternatives, and Valstar will provide a well-tolerated treatment option for these patients,” Endo president and CEO Dave Holveck said in a statement.